Limited Competition: John Lewis NIMHD Research Endowment Program (S21 Clinical Trial Not Allowed)

Academic PIs and research-administration leaders at minority-serving institutions have a $12 million, six-award NIH endowment competition to plan for: NIMHD forecast RFA-MD-28-001 on grants.gov on September 8, 2026 (opportunity 363826), with applications estimated due May 25, 2027.

What NIMHD Posted on September 8 — and What It Deliberately Left Out

The grants.gov forecast record for opportunity 363826 is thin by design. It carries an opportunity number — RFA-MD-28-001 — a title, a dollar figure, and a set of estimated dates. It does not carry a notice of funding opportunity, because the NOFO does not exist yet. NIMHD's estimated synopsis posting date is March 25, 2027, with an estimated application response date of May 25, 2027, an estimated award date of June 30, 2028, and a fiscal year 2028 designation.

The numbers attached to the forecast: $12,000,000 in estimated total program funding, an award ceiling of $2,000,000, and six anticipated awards. No cost sharing. Assistance Listing 93.307 (Minority Health and Health Disparities Research). The activity code is S21 — Research and Institutional Resources Health Disparities Endowment Grants — and clinical trials are not allowed, which for this mechanism is less a restriction than a category error: the program does not fund research projects at all.

That last point is the one that trips up PIs reading this as a normal NIH opportunity. Per the forecast text, quoting the statutory purpose, the program exists "to strengthen the research infrastructure and training capacity at eligible institutions of higher education to facilitate health disparities research," with four named strategic objectives: improving physical infrastructure and research equipment, developing research-enabling technical expertise, expanding academic science programs, and merit-based recruitment of accomplished researchers into open faculty lines. The forecast states flatly that the program "does not directly support research projects."

The Eligibility Screen Is the Entire Competition

The word doing the most work in the title is "Limited." NIMHD's forecast says this competition "will invite application(s) from eligible organization(s) to apply." Applications still go through standard NIH peer review, and only meritorious ones get funded — but the pool is defined before a single specific aim is written.

The statutory filter comes from section 464z-3(h) of the Public Health Service Act, 42 U.S.C. 285t(h), as amended by Public Law 117-104 — the John Lewis NIMHD Research Endowment Revitalization Act of 2021, signed March 18, 2022. Two tests apply. First, a Center of Excellence history: the institution must hold or have held a HRSA Center of Excellence award under Section 736 of the PHS Act, or a NIMHD Center of Excellence award under Section 464z-4. The 2021 law's actual contribution was the word "former" — before it, lapsed Centers of Excellence were locked out, which perversely penalized institutions whose COE funding had ended.

Second, and more decisive: the institution's endowment must be equal to or less than 50 percent of the national median of endowment funds at institutions conducting similar biomedical research and health-professions training. This is a wealth cap, and it is unusual in the NIH portfolio. Most NIH mechanisms are indifferent to an applicant's balance sheet. This one makes the balance sheet dispositive, and it cuts in the opposite direction from every instinct a research office has: growing your endowment past the threshold disqualifies you.

One drafting detail is worth flagging to your sponsored programs office now rather than in April 2027. The grants.gov forecast text describes eligible applicants as institutions with "current or former HRSA Centers of Excellence awards under Section 736 … and current or former NIMHD Centers of Excellence awards under Section 464z-4." The governing regulation at 42 CFR § 52i.3(a)(1) reads "or" — a current or former center of excellence under section 736 or section 464z-4. That is a meaningful difference for any institution holding one designation and not the other, and it is exactly the kind of question NIMHD program staff (NIMHDDCHPSSciTeam@mail.nih.gov) answer readily eighteen months out and grudgingly two weeks before a deadline.

An Endowment Is Not a Grant: The 20-Year Lock

Institutions that win an S21 do not receive spendable money. They receive corpus. The rules in 42 CFR Part 52i, last amended December 4, 2024, are stricter than most research administrators expect:

• The corpus must be invested no later than 90 days after the grant start date (§ 52i.7(c)).
• The full award amount must be maintained as corpus for 20 years from the end of the project period (§ 52i.7(e)). On a five-year award starting June 30, 2028, that is a lock running to roughly 2053.
• No part of the corpus may be withdrawn or spent during those 20 years (§ 52i.8(a)).
• Endowment income realized in the first year following the award may not be spent on programmatic activities until after the initial year concludes (§ 52i.9(a)).
• Spendable income is only the amount by which the fund's total value exceeds the corpus, calculated fresh at each planned withdrawal (§ 52i.10). If markets are down, there is nothing to spend, and the institution must take "appropriate actions" to preserve corpus value (§ 52i.7(f)).
• A final Financial Status Report is due 20 years after the end of the project period (§ 52i.11(d)).
• Violations — spending corpus, spending impermissible income, or failing the prudent-investor standard — trigger recovery of up to the full award plus any income earned (§ 52i.12).

The practical translation: a $10 million award at a conservative 4-to-5 percent payout throws off roughly $400,000 to $500,000 a year in spendable income, in perpetuity, starting in year two. That is not a capital infusion. It is an annuity — one faculty line, or equipment renewal, or a biostatistics core's operating budget, funded forever.

Why FY2028 Lands Exactly Where the Last Cohort Runs Out

The forecast's fiscal-year 2028 stamp is not arbitrary. On August 1, 2023, NIMHD announced awards to six institutional endowments totaling $60 million under the prior cycle, RFA-MD-22-010 (posted November 7, 2022; closed January 17, 2023). Recipients included Xavier University of Louisiana, which directed its endowment to its PREDICT Institute, and the University of North Texas Health Science Center at Fort Worth. Six awards, $60 million, five years — $10 million each, $2 million per year.

Now read § 52i.5(b): a prior grantee may apply for another grant under this part if it still meets the eligibility requirements and is in its last year of NIH funding under the program, or no longer has an active grant. A five-year award made in FY2023 reaches its final year in FY2028. The FY2028 competition is timed precisely so the 2023 cohort can recompete — and the six-award count in the forecast matches the six awards made in 2023 exactly.

That does not mean the outcome is predetermined. It does mean any institution outside the 2023 cohort should understand that it is competing against incumbents with a documented NIMHD-approved strategic plan, five years of endowment-management reporting, and an existing relationship with the program's scientific team. Renewal cycles reward the prepared incumbent; we saw the same dynamic in NCI's NCORP 2027 renewal cycle across RFA-CA-27-006, -007, and -008, where $147.5 million moved through a competition whose real work happened months before the NOFO published.

The $12 Million Figure Is Not a Cut

It is tempting to read "$12,000,000" against 2023's "$60 million" and conclude the program shrank by 80 percent. It did not. The grants.gov forecast reports the first-year obligation: a $2,000,000 award ceiling across six awards is $12 million in FY2028. Carried across a five-year project period at the same annual rate, that is $60 million total — the identical run rate as the 2023 cohort, which received $10 million each over five years.

The distinction matters if you are building a budget narrative or briefing a provost. The ask is $2 million per year for five years, accumulating to a $10 million corpus. Flat funding, not contraction. What has not changed since 2023 — and what any applicant should assume will not change — is that this is one of the smallest award counts in the NIH portfolio. Six awards, nationally, in a field of institutions that all meet the same statutory tests.

What Is Actually Worth Doing Between Now and March 2027

Eighteen months of lead time is unusual, and the work that moves the needle is not scientific writing.

Confirm the two eligibility tests in writing. Pull your institution's Section 736 and Section 464z-4 Center of Excellence award history — current or former — and get your current endowment market value benchmarked against the national median for comparable biomedical research and health-professions training institutions. Then email NIMHD program staff and ask them to confirm, specifically addressing the "and"/"or" discrepancy above.

Build the endowment management plan first. Section 52i.6 lists four review factors, and the fourth is "the adequacy of the applicant's plan for managing the endowment fund." Reviewers on this mechanism are evaluating your treasury operation alongside your science. Your CFO, investment committee, and affiliated foundation — if you intend to designate one under § 52i.4 — need to be at the table now, not in April 2027.

Write the strategic plan against the four statutory objectives. Endowment income can only be spent in accordance with a strategic plan approved by NIMHD (§ 52i.9(b)). Map infrastructure, technical expertise, academic program expansion, and faculty recruitment to specific, defensible line items.

Track the synopsis, not the forecast. Forecast dates move. March 25, 2027 is an estimate, and the real deadline arrives with the NOFO.

While the S21 window is still eighteen months out, institutional capacity-building money moves on many other mechanisms right now. Search active NIH research infrastructure and capacity-building opportunities on Granted to see what is open in the meantime — several NIH institutes run parallel infrastructure programs with far shorter lead times and no endowment lock.